Skip to content
Stanozolol
Winstrol (stanozolol) is a small molecule pharmaceutical. Stanozolol was first approved as Winstrol on 1984-05-14. It is known to target androgen receptor and estrogen receptor.
Download report
Favorite
Commercial
Therapeutic Areas
No data
Trade Name
FDA
EMA
No data
Drug Products
FDA
EMA
New Drug Application (NDA)
New Drug Application (NDA)
Abbreviated New Drug Application (ANDA)
Abbreviated New Drug Application (ANDA)
Stanozolol
Tradename
Company
Number
Date
Products
WINSTROLLundbeckN-012885 DISCN1984-05-14
1 products, RLD
Hide discontinued
Labels
FDA
EMA
No data
Indications
FDA
EMA
No data
Agency Specific
FDA
EMA
No data
Patent Expiration
No data
ATC Codes
A: Alimentary tract and metabolism drugs
— A14: Anabolic agents for systemic use
— A14A: Anabolic steroids
— A14AA: Androstan derivatives
— A14AA02: Stanozolol
HCPCS
No data
Clinical
Clinical Trials
41 clinical trials
View more details
Mock data
Subscribe for the real data
Indications Phases 4
No data
Indications Phases 3
Indication
MeSH
Ontology
ICD-10
Ph 1
Ph 2
Ph 3
Ph 4
Other
Total
InflammationD007249——1—12
Postoperative complicationsD011183——1——1
Indications Phases 2
No data
Indications Phases 1
Indication
MeSH
Ontology
ICD-10
Ph 1
Ph 2
Ph 3
Ph 4
Other
Total
Healthy volunteers/patients—1———45
Indications Without Phase
Indication
MeSH
Ontology
ICD-10
Ph 1
Ph 2
Ph 3
Ph 4
Other
Total
ObesityD009765EFO_0001073E66.9————33
Metabolic syndromeD024821EFO_0000195E88.81————22
Type 2 diabetes mellitusD003924EFO_0001360E11————22
Blood pressureD001794EFO_0004325————22
SarcopeniaD055948EFO_1000653M62.84————22
GrowthD006128————22
Milk hypersensitivityD016269EFO_0007369————22
CognitionD003071EFO_0003925————11
Muscle weaknessD018908HP_0001324————11
AgingD000375GO_0007568R41.81————11
Show 18 more
Epidemiology
Epidemiological information for investigational and approved indications
View more details
Drug
General
Drug common nameSTANOZOLOL
INNstanozolol
Description
Stanozolol is an organic heteropentacyclic compound resulting from the formal condensation of the 3-keto-aldehyde moiety of oxymetholone with hydrazine. Like oxymetholone, it is a synthetic anabolic steroid. It has both anabolic and androgenic properties, and has been used to treat hereditary angioedema and various vascular disorders. It has also been widely abused by professional athletes. It has a role as an androgen and an anabolic agent. It is a 17beta-hydroxy steroid, a tertiary alcohol, an anabolic androgenic steroid and an organic heteropentacyclic compound. It is functionally related to an oxymetholone.
Classification
Small molecule
Drug classbeta-blockers (propranolol type)
Image (chem structure or protein)
Structure (InChI/SMILES or Protein Sequence)
C[C@]12Cc3c[nH]nc3C[C@@H]1CC[C@@H]1[C@@H]2CC[C@@]2(C)[C@H]1CC[C@]2(C)O
Identifiers
PDB—
CAS-ID10418-03-8
RxCUI10032
ChEMBL IDCHEMBL2079587
ChEBI ID9249
PubChem CID25249
DrugBankDB06718
UNII ID4R1VB9P8V3 (ChemIDplus, GSRS)
Target
Agency Approved
No data
Alternate
AR
AR
ESR1
ESR1
Organism
Homo sapiens
Gene name
AR
Gene synonyms
DHTR, NR3C4
NCBI Gene ID
367
Protein name
androgen receptor
Protein synonyms
Dihydrotestosterone receptor, Nuclear receptor subfamily 3 group C member 4
Uniprot ID
Q9UD95
Mouse ortholog
Ar (11835)
androgen receptor (P19091)
Variants
Clinical Variant
No data
Financial
No data
Trends
PubMed Central
Top Terms for Disease or Syndrome:
Mock data
Subscribe for the real data
Additional graphs summarizing 1,001 documents
View more details
Safety
Black-box Warning
No Black-box warning
Adverse Events
Top Adverse Reactions
Mock data
Subscribe for the real data
9 adverse events reported
View more details